Review on Onychomycosis due to Non-Dermatophyte Mould: Advance Diagnosis and Treatment Process
DOI:
https://doi.org/10.71637/tnhj.v25i2.907Keywords:
Onychomycosis, Non- dermatophyte mould, Immunocompromised patients, AspergillusAbstract
Background: Onychomycosis is a chronic infection of the nail. The most common causative agent of onychomycosis due to non dermatophytic mould is Aspergillus.
Objectives: This review aims to address the various complications of onychomycosis due to non- dermatophyte mould and to provide an update on the diagnosis and treatment of onychomycosis.
Methods: Databases including PubMed, Google Scholar were searched to identify the relevant articles. The search strategies included case studies, research articles, and review papers published within the past 20 years.
Results: We reviewed all available literature concerning onychomycosis. A literature search revealed 130 studies, for this review paper we included 33 articles evaluating the onychomycosis due to non-dermatophyte mould. Five were case reports, five were research studies, two were cross- sectional studies, one was a randomized controlled trial, and the remaining were review and systematic reviews. In this, 3.03% of included publications have an impact factor more than 15, 6.06% have an impact factor more than 8, 81.81% have an impact factor ranging between 1-5, and 9.09% have an impact factor less than 1. From all the searched data it showed that toenails are more prone to infections than the fingernails.
Conclusion: Oral therapies are effective, but one disadvantage is that they have more side effects. Topical treatment is less effective and requires extended treatment because of the slow penetration to the nail plate but it has minimal adverse effects. Now, there are various new techniques that are quite promising like laser, photodynamic, plasma therapy, and oil from ethnomedicinal plants.
Downloads
References
1.Gibas CC, Wiederhold NP. Mycology of Onychomycosis. Clinic Microbiol Newslet. 2023; 45(2):11-17.
2. Behera JK, Kumar S, Sharma R, et al. Novel Discoveries and Clinical Advancements for Treating Onychomycosis: A Mechanistic Insight. Adv Drug Deliv Rev. 2024; 205:115174.
3.Conrado PCV, Vaine AA, Arita GS et al. Promising onychomycosis treatment with hypericin-mediated photodynamic therapy. Photodiagnosis Photodyn. Ther. 2023; 42:103498.
4.Pakshir K, Kamali M, Nouraei H et al. Molecular characterization and antifungal activity against nondermatophyte molds causing onychomycosis. Sci Rep. 2021; 11:20736.
5.Queller JN, Bhatia N. The dermatologist's approach to onychomycosis. J Fungi (Basel). 2015; 1(2): 173-84.
6.Gupta AK, Venkataraman M, Talukder M. Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management. Drugs Aging. 2022; 39(3):191-198.
7.Ehrensberger M, Boal CWC, Brennan J et al. A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails. J Mycol Med. 2022; 32(3):101256.
8.Lim SS, Ohn J, Mun JH. Diagnosis of Onychomycosis: From Conventional Techniques and Dermoscopy to Artificial Intelligence. Front Med. 2021; 8:637216.
9.Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. Am Fam Physician. 2021; 104(4):359-367.
10.Bongomin F, Batac CR, Richardson MD et al. A Review of Onychomycosis Due to Aspergillus Species. Mycopatholo. 2018; 183(3):485-493.
11.Tsang CC, Hui TW, Lee KC et al. Genetic diversity of Aspergillus species isolated from onychomycosis and Aspergillus hongkongensis sp. nov., with implications to antifungal susceptibility testing. Dia Microbiol Infect Dis. 2016; 84(2):125-34.
12.Piraccini BM, Alessandrini A. Onychomycosis: A Review. J Fungi. 2015; 1: 30-43.
13.Razavyoon T, Hashemi SJ, Mansouri P et al. The epidemiology and etiology of onychomycosis in 2 laboratory centers affiliated to Tehran university of medical sciences during 2019-2020. Iran J Microbiol. 2022; 14(2):268-275.
14.Leung AKC, Lam JM, Leong KF et al. Onychomycosis: An Updated Review. Recent Pat Inflam Allergy Drug Disco. 2020; 14(1):32-45.
15.Maskan Bermudez N, Rodríguez-Tamez G, Perez S et al. Onychomycosis: Old and New. J Fungi (Basel). 2023; 9(5):559.
16.Sharma A, Sumbali G. First Record of Aspergillus brunneus Causing Fingernail Aspergillomycosis in a Primary Schoolchild. Ind J Paedi Dermatol. 2022; 23(2):153-155.
17.Wijesuriya T M, Kottahachchi J, Gunasekara T D C P et al. Aspergillus species: An emerging pathogen in onychomycosis among diabetics. Ind J Endocrine and Metabolic. 2015; 19:811-6.
18.Dubljanin E, Dzamic A, Vujcic I et al. Correlation of clinical characteristics, by calculation of SCIO index, with the laboratory diagnosis of onychomycosis. Brazil J Microbiol. 2022; 53:221–229.
19.Falotico JM, Lipner SR. Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clin Cosme Invest Dermatol. 2022; 15:1933-1957.
20.Gupta AK, Stec N, Summerbell RC et al. Onychomycosis: a review. J Euro Aca Dermatol Venereol. 2020; 34(9):1972-1990.
21.Gupta AK, Mays RR. The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature. Skin Appendage Disorder. 2018; 4(4):208-216.
22.Kim DM, Suh MK, Ha GY et al. Fingernail Onychomycosis Due to Aspergillus niger. Ann Dermatol. 2012; 24(4):459-63.
23.Noguchi H, Matsumoto T, Kimura U et al. Non- dermatophyte Mould Onychomycosis in Japan, Med. Mycol. 2020; 61:23-31.
24.Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereo Lepro. 2012; 78(3):263-70.
25.Álvarez-Salafranca M, HernándezOstiz S, Salvo Gonzalo S et al. Onicomicosis subungueal proximal por Aspergillus niger: un simulador de melanoma maligno subungueal. Actas Dermo sifiliogra. 2017; 108:481- 484.
26.Litaiem N, Mnif E, Zeglaoui F. Dermoscopy of Onychomycosis: A Systematic Review. Dermatol Pra Concept. 2023; 13(1): 2023072.
27.Devi Sangeetha A, Gopalakrishnan K, Ramachandran R et al. descriptive study of onychoscopic features in various subtypes of onychomycosis. Med J Arm For Ind. 2022; 78(1):219-225.
28.Gupta AK, Ryder JE, Baran R, Summerbell RC. Non-dermatophyte onychomycosis. Dermatol Clin. 2003; 21(2):257-68.
29.Moreno G, Arenas R. Other fungi causing onychomycosis. Clin Dermatol. 2009; 28:160–3.
30.Shirwaikar AA, Thomas T, Shirwaikar A et al. Treatment of onychomycosis: an update. Indian J Pharm Sci. 2008; 70(6):710-4.
31.Grover C, Khurana A. Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereo Lepro. 2012; 78(3):263-70.
32.Barbosa Ribeiro T, Caetano Lira J A, Gonçalves Bezerra S M et al. Use of essential oils in onychomycosis: an integrative review. Revis Estima. 2021;19 (1321).
33.Nickles MA, Lio PA, Mervak JE. Complementary and Alternative Therapies for Onychomycosis. Skin Appendage Disord. 2022; 8 (4): 269–279.
Published
Issue
Section
License
Copyright (c) 2025 Mamalisa Sahoo, Gyanranjan Mahalik, Monali Priyadarsini Mishra, Dattatreya Kar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
